Navigation Links
Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function

SAN FRANCISCO, May 07, 2007 /PRNewswire/ -- Interim results from a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept(R) (mycophenolate mofetil) were presented at the American Transplant Congress. This and other Spare the Nephron (STN) trials in kidney and liver transplant recipients examine ways to prevent rejection without damaging kidneys.

As transplant patients are living longer, doctors are finding that older therapies such as steroids and calcineurin inhibitors (CNIs) can cause impairment of kidney function and damage to the blood vessels and filtering capacity of the kidneys.(1)(2) The STN trials are being conducted at more than 35 transplant centers in the United States and Canada and use CellCept and other immunosuppressants in combinations that reduce or eliminate the use of steroids and CNIs.

"Our goal for the Spare the Nephron trial in kidney transplant recipients is to determine the safest and most effective immunosuppressive therapy regimen that avoids the nephrotoxic effects of CNIs while preventing rejection," said Matthew Weir, M.D., professor and director of the division of nephrology at the University of Maryland School of Medicine. "The preliminary study results are very encouraging."

Dr. Weir reported that first-year results in kidney transplant recipients demonstrated that patients on CellCept and sirolimus maintenance therapy showed improvements in glomerular filtration rate (GFR) of their kidneys without increasing rejection rates.

A total of 208 of 305 kidney transplant patients completed 12 months of follow-up in this open-label, prospective, randomized, multicenter study. Patients initially treated with CellCept and a CNI were randomized to receive CellCept and sirolimus or to continue their current treatment regimen of CellCept and a CNI. Efficacy endpoints included the proportions of patients experiencing acute reject
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
2. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
3. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
4. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
5. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
6. Clinical Trial Excellence: Shaping Markets Through Early Communication of Clinical Trial Data
7. Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial
8. Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron
9. Immediate Treatment of Early MS Patients with Betaferon Significantly Delayed Permanent Disability
10. First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability
11. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
Post Your Comments:
(Date:9/19/2014)... LYNBROOK, N.Y. , Sept. 19, 2014  BioSpecifics Technologies ... first in class collagenase-based products marketed as XIAFLEX ® ... announced today that BioSpecifics, President, Tom Wegman , will ... BioCentury NewsMakers in the Biotech Industry Conference. ... at 3:00 p.m. EDT at the Millennium Broadway Hotel in ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia Therapeutics, ... clinical data for its lead candidate ITCA 650 (continuous ... with high baseline HbA1c levels at the 50 th ... Study of Diabetes (EASD). Data from the open-label, phase ... of blood sugar in patients with poorly controlled type ...
(Date:9/19/2014)... 19, 2014  PCI is pleased to announce ... is a leading provider of Clinical Trial Services ... Wales in the ... expands PCI,s presence in the UK/EU to support ... packaging, storage and distribution capacity, as well as ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... NEW YORK, Jan. 10, 2012  ( http://www.myprgenie.com/  ) ... Americans 10 years ago and ask them where they found ... their current healthcare provider in their insurance plan directory or ... that is not the case.  Eighty percent of all U.S. ...
... uVera Diagnostics has introduced the CR3 Keyless Split Sample Cup ... cup provides several state-of-the-art features not available together in any ... to the drug testing industry," said Rick Nee, president of ... of use for both genders. The unique patented device is ...
Cached Medicine Technology:Castle Connolly Makes Finding the Best Healthcare from Top Doctors Even Easier 2uVera Diagnostics Offers New Drug Screening Product 2
(Date:9/19/2014)... CA (PRWEB) September 19, 2014 In partnership ... has been an active part of the project’s social media ... movement, which aims to re-define the perception of beauty as ... Project began as an idea by Shelly Baer and Vanessa ... disabled women as sexy and beautiful. Ginny Dixon, Wendy Crawford, ...
(Date:9/19/2014)... Researchers at Jacksonville,s campus of Mayo Clinic have discovered ... contributes to both overproduction of toxic protein in the ... as loss of communication between neurons both significant ... in the online issue of Neuron ... with drugs "may rejuvenate or rescue this pathway," says ...
(Date:9/19/2014)... states are passing legislation permitting or requiring schools to ... having a severe allergic reaction. Epinephrine auto-injectors are ... can lead to throat swelling, breathing difficulties, a steep ... In people with severe allergies to certain foods, such ... drugs, anaphylaxis can occur within moments of exposure to ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
(Date:9/19/2014)... 2014 Capital Region Periodontics and ... excited to announce the latest addition to their ... and those needing dental implants. Often referred to ... removes the fear factor normally associated with traditional ... and bleeding make, this procedure a very attractive ...
Breaking Medicine News(10 mins):Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3
... Aug. 13 As reported in publications and news,outlets ... "buck" teeth was replaced at the summer games opening ... the decision spawned,disbelief around the globe, sadly, the phenomenon ... of their teeth is nothing new., In a ...
... donations for breast cancer,research/programs, DETROIT, Aug. 13 ... part to end cancer, as well as honor the ... goal of walking 18,marathons in 18 days -- The ... cancer research and programs at the Barbara Ann Karmanos ...
... 3 new reports raise question of how long a heart ... 13 (HealthDay News) -- Three new reports challenge current guidelines ... taking a heart from an infant organ donor. , There,s ... no question that there aren,t enough donor organs to save ...
... Weiner Says Calls for,Privatization and ,Reform, are Granny-on-Your-Own, ... WASHINGTON, Aug. 13 On Social Security,s,73rd Anniversary ... of Staff,Robert Weiner is saying, "Calls to ,reform, ... Street,giveaway which would turn Social Security from a ...
... Held Thursday, August 14, 2008 at 9:00 a.m. Eastern ... ... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reports operational and,financial results ... year 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "Alseres made solid ...
... -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" ... Republic of China,("PRC"), today announced that it will ... on Monday, August 18, 2008 to discuss results ... Dr. Zhongyi Liu, Chairman and Chief Executive Officer ...
Cached Medicine News:Health News:Summer Games 'Swap' Raises Questions About Image, Oral Health 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3Health News:Infant Heart Transplant Controversy Continues 2Health News:Infant Heart Transplant Controversy Continues 3Health News:Infant Heart Transplant Controversy Continues 4Health News:Social Security's 73rd Anniversary 2Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 2Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 3Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 4Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 5Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 6Health News:Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results 2
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: